Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROG phase 3 trial of 6 vs 18 months androgen deprivation with or without zoledronic acid in localized prostate cancer
ACTRN12607000097448Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Oct 2003
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of leuprolide and zoledronic acid in prostate adenocarcinoma and prostate cancer (PCa), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Prostate cancer-specific mortality. Started Oct 2003; status: completed.
02
Drugs
leuprolidezoledronic acid
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12607000097448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000097448.